Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Pharmacologic- and gene-based therapies have historically been developed as two independent therapeutic platforms for cystic fibrosis (CF) lung disease. Inhibition of the dysregulated epithelial Na channel (ENaC) is one pharmacologic approach to enhance airway clearance in CF. We investigated pharmacologic approaches to enhance CFTR gene delivery with recombinant adeno-associated virus (rAAV) and identified compounds that significantly improved viral transduction while simultaneously inhibiting ENaC activity through an unrelated mechanism. Treatment of human CF airway epithelia with proteasome modulating agents (LLnL and doxorubicin) at the time of rAAV2 or rAAV2/5 infection dramatically enhanced CFTR gene delivery and correction of CFTR-mediated short-circuit currents. Surprisingly, these agents also facilitated long-term (15-day) functional inhibition of ENaC currents independent of CFTR vector administration. Inhibition of ENaC activity was predominantly attributed to a doxorubicin-dependent decrease in gamma-ENaC subunit mRNA expression and an increase in gamma-ENaC promoter methylation. This is the first report to describe the identification of compounds with dual therapeutic action that are able to enhance the efficacy of CFTR gene therapy to the airway while simultaneously ameliorating primary aspects of CF disease pathophysiology. The identification of such compounds mark a new area for drug development, not only for CF, but also for other gene therapy disease targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucus clearance as a primary innate defense mechanism for mammalian airways
Knowles, M. R., & Boucher, R. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215217 · Cited by 1,054
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391
Self-citationDuan, D., Yue, Y., Yan, Z., & Engelhardt, J. F. (2000) · Nature Medicine · doi:10.1038/75080 · Cited by 200
Self-citation
Cited by
Moss, R. B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P. L., Clancy, J. P., Spencer, L. T., Pilewski, J., Waltz, D. A., Dorkin, H. L., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.022 · Cited by 277
Self-citationNanodelivery in airway diseases: Challenges and therapeutic applications
Roy, I., & Vij, N. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.07.001 · Cited by 137
Ostedgaard, L. S., Rokhlina, T., Karp, P. H., Lashmit, P., Afione, S., Schmidt, M., Zabner, J., Stinski, M. F., Chiorini, J. A., & Welsh, M. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409845102 · Cited by 105
Self-citationNicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
Tang, Y., Yan, Z., Lin, S., Huntemann, E. D., Feng, Z., Park, S.-Y., Sun, X., Yuen, E., & Engelhardt, J. F. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.008 · Cited by 21
Self-citation
Metadata
- Authors
- Zhang, L. N., Karp, P., Gerard, C. J., Pastor, E., Laux, D., Munson, K., Yan, Z., Liu, X., Godwin, S., Thomas, C. P., Zabner, J., Shi, H., Caldwell, C. W., Peluso, R., Carter, B., & Engelhardt, J. F.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 10
- Issue
- 6
- Pages
- 990-1002
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2053222398
- Cited by
- 50
- References
- 3
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway. https://app.cochat.ai/papers/10.1016/j.ymthe.2004.08.009
- The paper
- Zhang, L. N., Karp, P., Gerard, C. J., Pastor, E., Laux, D., Munson, K., Yan, Z., Liu, X., Godwin, S., Thomas, C. P., Zabner, J., Shi, H., Caldwell, C. W., Peluso, R., Carter, B., & Engelhardt, J. F. (2004). Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2004.08.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.